收藏切换
Effects of nafamostat mesilate anticoagulant on continuous renal replacement therapy in patients at high risk of bleeding after cardiovascular surgery
收藏切换
Wei ZHOU1, 2, Yun TAO2, Lin HAN2, Zhiyun XU2, Bailing LI2, *, Hao CHENG2, *
World Clinical Drug | 2022, 43(9) : 1143 - 1147
Less
收藏切换
World Clinical Drug | 2022, 43(9): 1143-1147
• Article •
Effects of nafamostat mesilate anticoagulant on continuous renal replacement therapy in patients at high risk of bleeding after cardiovascular surgery
Full
Wei ZHOU1, 2, Yun TAO2, Lin HAN2, Zhiyun XU2, Bailing LI2, *, Hao CHENG2, *
Affiliations
  • 1.Department of Critical Care Medicine, Shanghai East Hospital, Shanghai 200120, China
  • 2.Department of Cardiovascular Surgery, First Affiliated Hospital of Naval Medical University, Shanghai 200433, China
Published: 2022-09-10 doi: 10.13683/j.wph.2022.09.011
Outline
收藏切换
Objective

To investigate the effects of nafamostat mesilate as an anticoagulant in patients at high risk of bleeding after cardiovascular surgery undergoing continuous renal replacement therapy (CRRT).

Methods

Twenty-seven patients with high risk of bleeding who underwent CRRT after cardiovascular surgery in the first affiliated hospital of naval medical university from August 2021 to April 2022 were enrolled. According to the different anticoagulants, the patients were divided into anticoagulant group (nafamostat mesilate as anticoagulant, n=12) and non-anticoagulant group (n=15). The incidence of adverse events and the service life of the filter were compared between the two groups, and the coagulation indexes of the anticoagulation group during the treatment were further analyzed.

Results

The life of cardiopulmonary bypass through the first cannula was significantly longer than that in the non-anticoagulation group [(31.82±10.84) h vs (21.64±12.26) h, P=0.033]. The average service life of the filter during CRRT were also significantly longer than those in the non-anticoagulation group (P<0.05), Also, the incidence of bleeding events in the anticoagulation group was no increase throughout the treatment period.

Conclusion

It is safe and effective to use nafamostat mesilate as an anticoagulant in patients with high bleed risk after cardiovascular surgery during CRRT, which can effectively prolong the use time of the filter and no increase in the incidence of hemorrhagic complications.

nafamostat mesilate  /  cardiovascular surgery  /  continuous renal replacement therapy
周炜, 陶芸, 韩林, 徐志云, 李白翎, 程浩. 甲磺酸萘莫司他抗凝在心血管外科术后高危出血风险患者连续性肾脏替代治疗中应用. 世界临床药物, 2022 , 43 (9) : 1143 -1147 . DOI: 10.13683/j.wph.2022.09.011
Wei ZHOU, Yun TAO, Lin HAN, Zhiyun XU, Bailing LI, Hao CHENG. Effects of nafamostat mesilate anticoagulant on continuous renal replacement therapy in patients at high risk of bleeding after cardiovascular surgery[J]. World Clinical Drug, 2022 , 43 (9) : 1143 -1147 . DOI: 10.13683/j.wph.2022.09.011
Year 2022 volume 43 Issue 9
12
2
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.09.011
  • Receive Date:2022-04-18
  • Online Date:2026-11-19
  • Published:2022-09-10
Article Data
Affiliations
History
  • Received:2022-04-18
  • Revised:2022-09-02
Affiliations
    1.Department of Critical Care Medicine, Shanghai East Hospital, Shanghai 200120, China
    2.Department of Cardiovascular Surgery, First Affiliated Hospital of Naval Medical University, Shanghai 200433, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.09.011
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT